Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

2024 issues

Clinical pathology selected abstracts

September 2024—Syphilis, an infectious disease caused by the spirochete bacterium Treponema pallidum, can be transmitted by blood transfusion. Therefore, donor blood has been routinely screened for syphilis since the 1950s. Although a case of transfusion-transmitted syphilis has not been documented in more than 50 years, routine serological testing is still performed because there is not sufficient evidence that it is no longer necessary. Syphilis testing can contribute to disease monitoring for overall public health by identifying infected blood donors so they can seek treatment to prevent further spread. The Transfusion Transmissible Infections Monitoring System (TTIMS) monitors infectious disease and demographic changes in donors who contribute approximately 60 percent of the U.S. blood supply, including at four major blood-collection organizations.

Anatomic pathology selected abstracts

September 2024—Research has shown assessment of tumor-associated stroma to be of reliable prognostic value. The authors conducted a study in which they evaluated the prognostic value of tumor-stroma ratio in a large multicenter cohort of nasopharyngeal carcinoma. They used the conventional H&E-stained slides of 115 cases of nasopharyngeal carcinoma to assess tumor-stroma ratio as described in recent guidelines. The amount of tumor-associated stroma was assessed as a percentage and then tumors were classified as stroma high (more than 50 percent) or stroma low (50 percent or less). Kaplan-Meier curves, a χ2 test, and Cox regression univariable and multivariable analyses were conducted.

Molecular pathology selected abstracts

September 2024—Oncology patients may benefit greatly from whole genome sequencing. Previous studies have suggested that it can provide relevant information pertaining to pediatric cancers, especially in selected cohorts of patients with high-risk disease. However, its clinical utility has not been thoroughly explored in routine clinical practice. The authors of this study examined the benefits of whole genome sequencing (WGS) in a consecutive cohort of pediatric patients from two institutions who required molecular workup for hematological neoplasms and solid tumors. Great Ormond Street Hospital, London, and Cambridge (England) University Hospitals offered WGS to patients with leukemia or solid tumors, respectively.

Q&A column

September 2024
Q. When performing body fluid cell counts, we report total nucleated cells and RBCs. What cell categories should we report on the corresponding differential? Can we group together monocytes, macrophages, and mesothelial cells since it is difficult to distinguish reactive mesothelial cells from monocytes and macrophages? If so, what category name should be applied? Should we report mesothelial cells as a comment or include them in the differential? Read answer.
Q. Are nonlaboratory personnel who perform point-of-care testing required to be tested for visual color discrimination? Or is it sufficient that personnel pass a functional assessment during their competency evaluation to evaluate their ability to provide an accurate result on tests that require interpreting colors? Read answer.

Newsbytes

September 2024—The ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine has created the Sherrie Perkins Research and Innovation Collaboration grant to fund lab medicine research that has the potential to significantly improve patient care.

Put It on the Board

September 2024—The Association for Molecular Pathology and pathologist Michael Laposata, MD, PhD, announced on Aug. 19 the filing of a lawsuit challenging the Food and Drug Administration rule that regulates laboratory-developed test procedures as medical devices under the Federal Food, Drug, and Cosmetic Act. The lawsuit was filed in the U.S. District Court for the Southern District of Texas against the FDA; Robert M. Califf, MD, in his official capacity as commissioner of food and drugs; the U.S. Department of Health and Human Services; and Xavier Becerra, in his official capacity as secretary of HHS.

LDT thoughts offer nuance, and advice

Two roads diverged in a regulated wood—and here comes Joe Lennerz, MD, PhD, happy not to be traveling both. As Dr. Lennerz considers this spring’s final rule from the FDA that regulates laboratory-developed tests as medical devices, he’s also kept an eye on the range of responses to the agency’s actions. One path is, broadly speaking, reactive; the other, proactive. He sees himself as a traveler on the latter road. This is perhaps unsurprising; he readily acknowledges he has professional sympathies with oversight agencies. He’s on the federal advisory panel for the Centers for Medicare and Medicaid Services. He also helped launch a group, the self-evidently named Pathology Innovation Collaborative Community, that includes FDA participation. “So I’ve been involved—let’s call it active collaborating—in this with the agency [FDA] for a number of years, at least since 2018,” he says. His motive is simple, his stride confident: “You can wait for regulation—guidance, final rules—to drop. Or you can become proactively involved. I am not reactionary. I always look to talk to the agency rather than criticize them.”

Lab test use: what 1 billion claims tell us

August 2024—Scale back excessive laboratory testing and use the savings to test the undertested and to fund unreimbursed tests, such as molecular diagnostics, suggest the authors of a large-scale study that found significant overuse of four tests. 

Picture of clinical metagenomic NGS comes into view

August 2024—The number of laboratories performing clinical metagenomic next-generation sequencing is limited, as is the number of sample types for which it’s available, but the range of pathogens mNGS detects is wide open.

What studies show for extended-life cryoprecipitate

August 2024–Extended-life cryoprecipitate has several pluses: longer shelf life, preserved fibrinogen function, and low risk of bacterial contamination, among others. “The big con is cost,” said Jay Hudgins, DO, MS, director of hemostasis and thrombosis, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio.

MARKETPLACE

TRENDING